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Biologics, including antibodies, hormones and cytokines, represent an increasingly important class of 
therapeutics, with 7 of the 10 top selling drugs from 2013 in this class.  The glycosylation distribution of these 
proteins is an important characteristic that can impact biological activity, circulatory half-life, and immunogenicity.  
One property that affects glycoproteins is the terminal addition of N-acetylneuraminic acid (sialic acid) to 
glycosylation chains.  Despite the importance of glycosylation in many therapeutic proteins, limited information is 
available to date linking process parameters to changes in glycosylation distribution.  The majority of the work that 
has been done is limited to a small number of proteins (such as interferon gamma) and small scale systems 
(shake flasks and bench top bioreactors).  Although this work represents a useful starting point, glycosylation is a 
parameter that is known to be influenced by production scale. 
Here we examine a glycosylated CHO fusion protein for which sialyation level is known to impact protein quality.  
Variation in this parameter was observed across pilot and manufacturing scale batches.  In order to better 
understand and control the biological source of the variation in the process, we employed metabolomic and 
transcriptomic methods, and successfully identified metabolic biomarkers, such as extracellular mannose, for 
sialylation level.  Additional studies demonstrated that changes to sugar metabolism were contributing to a build-
up of intermediates and inhibition of glycan sialyation, thereby identifying the biological source of variation in the 
process.  As a result of these studies, we evaluated the impact of process modifications including feed composition 
and gassing to enable consistent control of sialyation profiles.  
This work represents a novel contribution to the field.  We examine sialyation control of a CHO fusion protein at 
laboratory and manufacturing scale.  Furthermore, we combine ‘Omics techniques with bioprocess and analytical 
data to achieve a more detailed understanding of cell expression and metabolism [1], and leverage this 
understanding to refine the process and control a quality attribute.  Finally, this approach can be generalized 
beyond this specific process and applied to additional cell lines where undesired process variation is observed. 
 
 
1. Lewis, A.M., et al., The Use of ‘Omics Technology to Rationally Improve Industrial Mammalian Cell Line 
Performance. Biotechnology and Bioengineering, 2015: 10.1002/bit.25673 
 
